Search results
Results From The WOW.Com Content Network
Founded in 1999 by Milwaukee television journalist Melodie Wilson Oldenburg, After Breast Cancer Diagnosis provides resources to women in Wisconsin and nationwide who have been diagnosed with ...
Breast cancer is not a gender-specific disease; anyone who has breast tissue has a risk of getting breast cancer. Gendering guidelines for breast cancer excludes individuals who do not identify as female, which can potentially lead to late detection of breast cancer in those individuals.
Mammography is a common screening method, since it is relatively fast and widely available in developed countries. Mammography is a type of radiography used on the breasts. . It is typically used for two purposes: to aid in the diagnosis of a woman who is experiencing symptoms or has been called back for follow-up views (called diagnostic mammography), and for medical screening of apparently ...
For years, the city clinic had provided mammograms important for the early detection of breast cancer and other screenings through the Well Woman Program, a federally and state-funded program that ...
Ald. JoCasta Zamarripa criticized the Milwaukee Health Department for quietly ending women's preventive screenings at a south side clinic. A Milwaukee clinic quietly ended breast cancer screenings.
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
In response to her diagnosis, her close friends launched the TNBC Foundation to raise awareness and support research for this particular type of breast cancer. [2] Block-Zenna died of the disease in 2007, 2 1 ⁄ 2 years after her diagnosis. [2] At the time, little was known about triple negative breast cancer, and research efforts were minimal.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.